Published in JAMA on April 03, 2013
Antibodies against a secreted product of Staphylococcus aureus trigger phagocytic killing. J Exp Med (2016) 1.47
Staphylococcal manipulation of host immune responses. Nat Rev Microbiol (2015) 1.42
Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. MBio (2013) 1.26
Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect (2014) 1.18
Vaccines for the 21st century. EMBO Mol Med (2014) 1.17
Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. Front Immunol (2014) 1.13
The staphylococcal toxins γ-haemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat Commun (2014) 1.11
Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun (2014) 1.05
Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A (2015) 1.03
Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis (2013) 1.00
Will there ever be a universal Staphylococcus aureus vaccine? Hum Vaccin Immunother (2013) 0.97
Neutrophil-Mediated Phagocytosis of Staphylococcus aureus. Front Immunol (2014) 0.93
Differential Interaction of the Staphylococcal Toxins Panton-Valentine Leukocidin and γ-Hemolysin CB with Human C5a Receptors. J Immunol (2015) 0.93
Staphylococcus aureus protein A promotes immune suppression. MBio (2013) 0.91
Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun (2013) 0.91
Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study. Hum Vaccin Immunother (2015) 0.90
Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum Vaccin Immunother (2014) 0.90
Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters. J Orthop Res (2014) 0.89
Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye. Infect Immun (2014) 0.88
Zero tolerance for healthcare-associated MRSA bacteraemia: is it realistic? J Antimicrob Chemother (2014) 0.86
Exploiting dominant-negative toxins to combat Staphylococcus aureus pathogenesis. EMBO Rep (2016) 0.86
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. Hum Vaccin Immunother (2015) 0.85
Prevention of Recurrent Staphylococcal Skin Infections. Infect Dis Clin North Am (2015) 0.84
Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans. Hum Vaccin Immunother (2013) 0.84
Pathogenesis of Staphylococcus aureus Bloodstream Infections. Annu Rev Pathol (2016) 0.83
Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection. PLoS Pathog (2015) 0.82
Staphylococcus aureus vaccines: Deviating from the carol. J Exp Med (2016) 0.82
Innate Immune Signaling Activated by MDR Bacteria in the Airway. Physiol Rev (2016) 0.81
Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections. Trends Pharmacol Sci (2015) 0.81
Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine. Open Forum Infect Dis (2014) 0.81
Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection. Infect Immun (2014) 0.80
Vaccines for Acinetobacter baumannii: thinking "out of the box". Vaccine (2014) 0.80
Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection. MBio (2016) 0.80
Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates. Infect Immun (2014) 0.80
Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs (2015) 0.79
Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies. Microbiology (2015) 0.79
Adult vaccination. Hum Vaccin Immunother (2014) 0.79
Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther (2015) 0.79
MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers. Front Immunol (2015) 0.78
Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in mice. PLoS One (2015) 0.78
Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus. Front Immunol (2014) 0.78
Proteomic Identification of saeRS-Dependent Targets Critical for Protective Humoral Immunity against Staphylococcus aureus Skin Infection. Infect Immun (2015) 0.77
Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease. MBio (2016) 0.77
Current controversies in infective endocarditis. F1000Res (2015) 0.77
The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis. Microbiology (2016) 0.76
Characterization of the biological anti-staphylococcal functionality of hUK-66 IgG1, a humanized monoclonal antibody as substantial component for an immunotherapeutic approach. Hum Vaccin Immunother (2014) 0.76
Global antibody response to Staphylococcus aureus live-cell vaccination. Sci Rep (2016) 0.76
Comparative Exoproteomics and Host Inflammatory Response in Staphylococcus aureus Skin and Soft Tissue Infections, Bacteremia, and Subclinical Colonization. Clin Vaccine Immunol (2015) 0.76
Protein A suppresses immune responses during Staphylococcus aureus bloodstream infection in guinea pigs. MBio (2015) 0.76
Use of surveillance data to identify target populations for Staphylococcus aureus vaccines and prevent surgical site infections: a pilot study. Hum Vaccin Immunother (2014) 0.75
Identification of the immunodominant regions of Staphylococcus aureus fibronectin-binding protein A. PLoS One (2014) 0.75
Preventing postoperative Staphylococcus aureus infections: the search continues. JAMA (2013) 0.75
Infective endocarditis. Nat Rev Dis Prim (2016) 0.75
Staphylococcus aureus Protein A Disrupts Immunity Mediated by Long-Lived Plasma Cells. J Immunol (2016) 0.75
Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia models. Sci Rep (2016) 0.75
The T Cell Response to Staphylococcus aureus. Pathogens (2016) 0.75
Humanized Mouse Models of Staphylococcus aureus Infection. Front Immunol (2017) 0.75
Orthopaedic device-related infection: current and future interventions for improved prevention and treatment. EFORT Open Rev (2017) 0.75
Expression, immunogenicity and variation of iron-regulated surface protein A from bovine isolates of Staphylococcus aureus. FEMS Microbiol Lett (2017) 0.75
Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease. Infect Immun (2016) 0.75
Vaccines for Healthcare-associated Infections: Promise and Challenge. Clin Infect Dis (2016) 0.75
Improving vaccine trials in infectious disease emergencies. Science (2017) 0.75
Superantigens of a superbug: Major culprits of Staphylococcus aureus disease? Virulence (2016) 0.75
Epic Immune Battles of History: Neutrophils vs. Staphylococcus aureus. Front Cell Infect Microbiol (2017) 0.75
Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study. Diabetol Metab Syndr (2017) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis (2002) 11.30
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2008) 9.57
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med (2002) 9.21
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 8.20
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med (2009) 7.82
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother (2009) 6.33
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol (2005) 5.86
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Loss of vaccine-induced immunity to varicella over time. N Engl J Med (2007) 4.55
Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother (2006) 4.50
Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2008) 4.48
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47
Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis (2010) 4.25
Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis (2003) 4.06
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother (2007) 4.03
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis (2008) 3.93
Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother (2007) 3.74
In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70
High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother (2007) 3.62
Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother (2007) 3.55
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2006) 3.33
Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med (2003) 3.31
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect (2011) 3.10
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant (2010) 3.10
Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother (2006) 3.09
Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA (2007) 3.03
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis (2002) 2.99
Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA (2008) 2.95
First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother (2008) 2.93
The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis (2003) 2.92
Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA (2004) 2.90
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis (2011) 2.89
Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol (2007) 2.85
Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis (2004) 2.83
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis (2008) 2.73
Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med (2002) 2.68
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ (2011) 2.61
Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis (2005) 2.52
Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother (2008) 2.38
Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2005) 2.36
Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant (2010) 2.35
Clinical predictors of major infections after cardiac surgery. Circulation (2005) 2.27
Early predictors of in-hospital death in infective endocarditis. Circulation (2004) 2.26
An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med (2013) 2.23
Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med (2010) 2.17
Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology (2004) 2.16
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 2.15
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis (2005) 2.10
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis (2003) 2.02
Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation (2010) 2.01
Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother (2002) 2.00
Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med (2002) 2.00
Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis (2007) 2.00
Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258. Antimicrob Agents Chemother (2010) 1.97
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis (2005) 1.95
Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis (2009) 1.92
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis (2005) 1.92
Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis (2004) 1.91
Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J (2004) 1.90
High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2005) 1.90
A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med (2011) 1.88
Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis (2004) 1.87
A cross-national study of subjective sexual well-being among older women and men: findings from the Global Study of Sexual Attitudes and Behaviors. Arch Sex Behav (2006) 1.87
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother (2006) 1.84
Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. Clin Infect Dis (2009) 1.83
Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol (2004) 1.80
Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis (2009) 1.80
Native valve endocarditis due to coagulase-negative staphylococci: report of 99 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis (2004) 1.80
Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis (2007) 1.78
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol (2005) 1.77
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc (2010) 1.76